Industry Roundup: GNC, Sanofi And Bayer Earnings, 'Miracle Supplement' Fraud Conviction
This article was originally published in The Tan Sheet
Executive Summary
GNC CEO slams Oregon charges; Allegra, Nasacort key for Sanofi consumer; Consumer boosts Bayer; 'Miracle Supplement' seller sentenced; and more news in brief.
You may also be interested in...
Autism 'Cure' Products Spur Comment Wave On FDA's VMS Industry Oversight
More than half the 73 comments posted to FDA's DSHEA modernization docket are from consumers concerned about a specific type of product, bleach-containing liquids marketed as a cure for autism.
Health & Wellness Industry Roundup: July 11-15
Compromise GMO legislation passes House; private equity looks for health, wellness investments, including China; and more news in brief.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.